Information Provided By: 
Fly News Breaks for June 2, 2015
RARE
Jun 2, 2015 | 11:58 EDT
Wedbush said talks with regulators suggest Ultragenyx may be able to file for conditional approval of KRN23 in Europe once 40-week data in pediatrics is accrued, which is ahead of the firm's prior expectation, and clarity on a pivotal trial in adults sets a "clear path" to approval for the drug. The firm raised its price target on the stock to $102 from $74 and reiterates its Outperform rating on Ultragenyx shares.
News For RARE From the Last 2 Days
